Obesity is associated with different cancers including breast cancer, whose incidence is increased in postmenopausal women. It has an adverse impact on the prognosis of the patients, regardless of their menopausal status. The fact of receiving a systemic adjuvant therapy does not neutralize the prognostic role of obesity. Moderate weight loss after cancer diagnosis could improve the outcome of the patients, while a weight gain during treatment seems without significant effect. Currently available data are still too incomplete to justify systematic programs to lose weight with an oncologic therapeutic aim. However, it is worth to encourage and support our patients to have an optimal diet, physical activity, and to lose weight as promotion of general health.
"Many researchers have concluded that breast cancer is the cumulative result of multiple environmental factors and genetic alterations . Risk factors for breast cancer include estrogen stimulation , high birth weight , obesity , and family history of breast cancer [6, 7]. In addition, genome-wide association studies provide evidence that genetic factors are important in the pathogenesis of breast cancer . "
[Show abstract][Hide abstract] ABSTRACT: The vitamin D receptor (VDR) is a crucial mediator for the cellular effects of vitamin D. A great number of studies regarding the association between BsmI polymorphism in the VDR gene and breast cancer have been published. However, the results have been contradicting. Therefore, we conducted a meta-analysis to re-examine the controversy. Published literatures from PubMed, Embase, and Chinese Biomedical Literature Database (CBM) were searched (updated to July 10, 2013). The principal outcome measure was the odds ratio (OR) with 95 % confidence interval (CI) for breast cancer risk associated with VDR BsmI polymorphism. With all studies involved, the meta-analysis results suggest no statistically significant association between VDR BsmI polymorphism and breast cancer risk (B vs. b, OR = 0.922, 95 % CI = 0.836–1.018, P = 0.108, I2
= 80.0 %; BB vs. bb, OR = 0.843, 95 % CI = 0.697–1.021, P = 1.75, I2
= 75.5 %; Bb vs. bb, OR = 0.930, 95 % CI = 0.814–1.063, P = 0.31, I2
= 73.1 %; BB+Bb vs. bb, OR = 0.906, 95 % CI = 0.787–1.043, P = 1.37, I2
= 78.7 %; BB vs. bb+Bb, OR = 0.899, 95 % CI = 0.786–1.028, P = 1.56, I2
= 61.0 %). The results were not changed when studies were stratified by ethnicity or source of controls. This meta-analysis suggested that there were no associations between VDR BsmI polymorphism and breast cancer.
"Many studies have concluded that breast cancer is the cumulative result of multiple environmental factors and genetic alterations [5, 6]. Previous studies have suggested that the stimulation of estrogen , high weight of birth , obesity , and family history of breast cancer [10, 11] were associated with increased risk of breast cancer especially in postmenopausal women. But not all people exposed to these risk factors are suffering from breast cancer, which indicated that genetic plays an important role in the development of breast cancer. "
[Show abstract][Hide abstract] ABSTRACT: The association between xeroderma pigmentosum complementation group D (XPD) Asp312Asn and Lys751Gln gene polymorphisms and breast cancer risk has been widely reported, but the results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. A comprehensive search strategy was conducted towards the electronic databases including Medline, PubMed, Web of Science, Embase, and Chinese Biomedical Literature Database (Chinese). The association between the XPD polymorphism and breast cancer risk was conducted by odds ratios (ORs) and 95 % confidence intervals (95 % CIs). A total of 22 studies with 18,136 cases and 18,351 controls were included in our meta-analysis. Among these, 12 studies with 7,667 cases and 7,480 controls for Asp312Asn polymorphism and 20 studies with 10,469 cases and 10,871 controls for Lys751Gln polymorphism. With regard to Asp312Asn polymorphism, no significantly associated was found with breast cancer risk. However, significant association was found between Lys751Gln polymorphism and breast cancer risk under all genetic models in overall populations (C vs. A-OR = 1.10, 95 % CI = 1.04-1.17, P = 0.002; CC vs. AA-OR = 1.17, 95 % CI = 1.06-1.30, P = 0.003; AC vs. AA-OR = 1.06, 95 % CI = 1.01-1.12, P = 0.032; CC vs. AC/AA-OR = 1.17, 95 % CI = 1.04-1.32, P = 0.009; CC/AC vs. AA-OR = 1.07, 95 % CI = 1.02-1.12, P = 0.005). In subgroup analysis base on ethnicity, significance was found in Caucasians and mix. The results suggest that XPD Asp312Asn polymorphism was not associated with breast cancer. The XPD Lys751Gln polymorphism significantly increased breast cancer risk, especially for Caucasian and mix.
"Many researchers have concluded that BC is the cumulative result of multiple environmental factors and genetic alterations . Epidemiological studies have suggested that estrogen stimulation , high birth weight , obesity  and family history of BC ,  may be associated with increased risk of BC in postmenopausal women. However, only some patients with family history of BC develop malignancy; most cases of BC are sporadic. "
[Show abstract][Hide abstract] ABSTRACT: The onset and progression of breast cancer (BC) is influenced by many factors, including the single nucleotide polymorphism (SNP) rs13281615 at 8q24. However, studies of the potential association between rs13281615 at 8q24 and risk of BC have given inconsistent results. We performed a meta-analysis to address this controversy.
PubMed, EMBASE and the Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. Two curators independently extracted data, and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to assess the strength of the association between rs13281615 at 8q24 and risk of BC.
Fourteen studies are included in the meta-analysis, involving 44,283 cases (5,170 Chinese and 39,113 mixed) and 55,756 controls (5,589 Chinese and 50,167 mixed). The GG and G-allele genotypes of rs13281615 at 8q24 are significantly associated with increased risk of BC (GG vs. AG+AA, OR 1.13, 95% CI 1.08-1.19, P<0.001; G-allele vs. A-allele, OR 1.10, 95% CI 1.06-1.14, P<0.001; GG vs. AA, OR 1.20, 95% CI 1.12-1.29, P<0.001). Conversely, the AA genotype is significantly associated with decreased risk of BC (AA vs. AG+GG, OR 0.89, 95% CI 0.84-0.93, P<0.001).
G-allele genotypes of rs13281615 at 8q24 polymorphism are a risk factor for developing BC, while the AA genotype is a protective factor. Further large and well-designed studies are required to confirm this conclusion.
PLoS ONE 04/2013; 8(4):e60108. DOI:10.1371/journal.pone.0060108 · 3.23 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.